Blood Medicine. Blowing the Whistle on One of the Deadliest Prescription Drugs Ever

Par : Kathleen Sharp
Offrir maintenant
Ou planifier dans votre panier
Disponible dans votre compte client Decitre ou Furet du Nord dès validation de votre commande. Le format ePub protégé est :
  • Compatible avec une lecture sur My Vivlio (smartphone, tablette, ordinateur)
  • Compatible avec une lecture sur liseuses Vivlio
  • Pour les liseuses autres que Vivlio, vous devez utiliser le logiciel Adobe Digital Edition. Non compatible avec la lecture sur les liseuses Kindle, Remarkable et Sony
  • Non compatible avec un achat hors France métropolitaine
Logo Vivlio, qui est-ce ?

Notre partenaire de plateforme de lecture numérique où vous retrouverez l'ensemble de vos ebooks gratuitement

Pour en savoir plus sur nos ebooks, consultez notre aide en ligne ici
C'est si simple ! Lisez votre ebook avec l'app Vivlio sur votre tablette, mobile ou ordinateur :
Google PlayApp Store
  • Nombre de pages448
  • FormatePub
  • ISBN978-1-101-61713-7
  • EAN9781101617137
  • Date de parution28/08/2012
  • Protection num.Adobe DRM
  • Taille810 Ko
  • Infos supplémentairesepub
  • ÉditeurPlume

Résumé

"Blood Feud rivals A Civil Action for best non-fiction book of the past twenty years." - John Lescroart, New York Times bestselling author of Damage Procrit seemed like a biotech miracle, promising a golden age in medical care. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant, Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billions in annual revenue-and still does.  In 2012, world famous cyclist, Olympian, and Tour de France champion Lance Armstrong was banned from professional cycling on doping charges for using EPO (the blanket name for the drugs Procrit and Epogen), resulting in a global controversy about abuse, big pharmaceutical companies, and the lies and inaccuracies concerning performance-enhancing drugs.
Mark Duxbury was a J&J salesman who once believed in the blood-booster, setting record sales and winning company awards. Then Duxbury started to learn unsavory truths about Procrit and J&J's business practices. He was fired and filed a whistleblower suit to warn the public. When Jan Schlichtman (A Civil Action) learned of Duxbury's crusade, he signed on. Now, he's fighting on behalf of cancer patients and for every American who trusts Big Pharma with his life.
"Blood Feud rivals A Civil Action for best non-fiction book of the past twenty years." - John Lescroart, New York Times bestselling author of Damage Procrit seemed like a biotech miracle, promising a golden age in medical care. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant, Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billions in annual revenue-and still does.  In 2012, world famous cyclist, Olympian, and Tour de France champion Lance Armstrong was banned from professional cycling on doping charges for using EPO (the blanket name for the drugs Procrit and Epogen), resulting in a global controversy about abuse, big pharmaceutical companies, and the lies and inaccuracies concerning performance-enhancing drugs.
Mark Duxbury was a J&J salesman who once believed in the blood-booster, setting record sales and winning company awards. Then Duxbury started to learn unsavory truths about Procrit and J&J's business practices. He was fired and filed a whistleblower suit to warn the public. When Jan Schlichtman (A Civil Action) learned of Duxbury's crusade, he signed on. Now, he's fighting on behalf of cancer patients and for every American who trusts Big Pharma with his life.